Abstract: Fracture reduction tool is disclosed for use with a guide wire for reducing a bone fracture. The guide wire is of a uniform diameter and has a beaded end for placement into the medullary canal. The tool includes an elongated hollow shaft which can be passed into the medullary canal of the fractured bone through an entry hole prepared in the bone. The shaft has a bore along its length through which the guide wire can selectively pass. The shaft and/or the guide wire can be manipulated into and within the respective medullary canal portions of the fractured bone by translational and/or rotational movements so as to reduce the fracture. The tool also includes a measurement sleeve which moves over the shaft and provides a determination of the length of a nail to be inserted into the medullary canal of the reduced bone. A handle for the proximal end of the shaft allows for ease in manipulation of the shaft and guide wire.

Abstract: The cutting head for a surgical reamer has a leading end for insertion into a bone canal and a trailing end for attachment to a drive shaft. The cutting head has a cutting surface formed about an axis of rotation of the cutting head. The cutting surface is formed by the rotation of the cutting edges on a plurality of flutes spaced around the axis of rotation. Each cutting edge has a first portion spaced a predetermined radial distance from the axis of rotation at the tip portion and terminates at a terminating point which is at a greater radial distance from the axis of rotation than the starting point. The cutting edge on each flute has a second portion having a starting point at the trailing end of the cutting head which is at a second predetermined radial distance from the axis of rotation. The second portion extends axially towards the tip portion and terminates at a point at a greater radial distance from the axis of rotation than the starting point thereof.

Abstract: This invention relates to the use of tenidap, presently shown as the enolic form of 5-chloro-2,3-dihydro-2-oxo-3-(2-thienylcarbonyl)-indole-1-carboxamide, and the pharmaceutically-acceptable base salts thereof to reduce total serum cholesterol, LDL cholesterol and triglycerides in a mammal having an inflammatory arthritic condition. The methods of this invention comprise administering an effective amount of tenidap or salts thereof to a mammal.

Abstract: Anxiolytic agents which are racemic or optically active pyrido[1,2-a]pyrazine derivatives of the formula ##STR1## wherein x is N or CH and Y represents one of certain pyrazolo, triazolo, tetrazolo or cyclic imido radicals; and intermediates therefor.

Abstract: Hypoglycemic thiazolidine-2,4-dione derivatives of the formula ##STR1## wherein the dotted line represents a bond or no bond; A and dB are each independently CH or N, with the proviso that when A or B is N, the other is CH;X is S, SO, SO.sub.2, CH.sub.2, CHOH or CO;n is 0 or 1;Y is CHR.sup.1 or NR.sup.2, with the proviso that when n is 1 and Y is NR.sup.2, X is SO.sub.2 or CO;Z is CHR.sup.3, CH.sub.2 CH.sub.2, CH.dbd.CH, ##STR2## OCH.sub.2, SCH.sub.2, SOCH.sub.2 or SO.sub.2 CH.sub.2 ; R, R.sup.1, R.sup.2 and R.sup.3 are each independently hydrogen or methyl; andX.sup.1 and X.sup.2 are each independently hydrogen, methyl, trifluoromethyl, phenyl, benzyl, hydroxy, methoxy, phenoxy, benzyloxy, bromo, chloro or fluoro; a pharmaceutically-acceptable cationic salt thereof; or a pharmaceutically-acceptable acid addition salt thereof when A or B is N.

Abstract: Platelet activating factor antagonists of formula (I): ##STR1## wherein R is phenyl or phenyl substituted by one or more substituents selected from nitro, halo, C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, aryl(C.sub.1 -C.sub.4)alkoxy, fluoro(C.sub.1 -C.sub.4)alkoxy, C.sub.1 -C.sub.4 alkylthio, C.sub.1 -C.sub.4 alkylsulphonyl, hydroxy, trifluoromethyl and cyano, or is phenyl fused to a dioxole ring;R.sup.1 and R.sup.2 are each independently H or C.sub.1 -C.sub.6 alkyl, or R.sup.1 and R.sup.2 together complete a pyrrolidinyl, piperidino, morpholino, piperazinyl, N-(C.sub.1 -C.sub.4 alkyl)piperazinyl or N-(C.sub.2 -C.sub.4 alkanoyl)-piperazinyl group;R.sup.2 is H or C.sub.1 -C.sub.4 alkyl and R.sup.1 is CN, C.sub.3 -C.sub.7 cycloalkyl, aryl, heteroaryl or a C.sub.1 -C.sub.4 alkyl group substituted by one or more substituents selected from C.sub.3 -C.sub.7 cycloalkyl, C.sub.1 -C.sub.4 alkoxycarbonyl, aryl or heteroaryl;Z is selected from C.sub.1 -C.sub.6 alkoxy, aryl(C.sub.1 -C.sub.

Abstract: Certain cephalosporin compounds, and their pharmaceutically- accepted salts or in vivo hydrolyzable esters are useful as antibacterial agents.

Abstract: Certain enol ethers and esters of the formula ##STR1## where X and Y are each hydrogen, fluoro or chloro; R.sup.1 is 2-thienyl or benzyl and R is alkanoyl, cycloalkylcarbonyl, phenylalkanoyl, chlorobenzoyl, methoxybenzyl, phenyl, thenoyl, omega-alkoxycarbonylalkanoyl, alkoxycarbonyl, phenoxycarbonyl, 1-alkoxyalkyl, 1-alkoxycarbonyloxyalkyl, alkyl, alkylsulfonyl, methylphenylsulfonyl or dialkylphosphonate are useful as prodrug forms the known 3-acyl-2-oxindole-1-carboxamide antiinflammatory and analgesic agents.

Abstract: The present invention comprises a first interconnect assembly and a second interconnect assembly which detachably connects to the first interconnect assembly. One of the interconnect assemblies includes a shutter for blocking an optical path. The first and second assemblies have surfaces which mechanically co-act to drive the shutter away from the optical path. An optical fiber is connected to one of these assemblies. In the preferred embodiment, the first assembly forms a plug and the second assembly forms an adapter, such as a socket. The socket assembly includes a shutter which is spring-biased to a normally closed position. In this normally closed position, the shutter blocks passage of laser light of the optical fiber. The plug assembly includes an appendage having a camming surface which co-acts with a camming surface on the socket assembly so as to drive the shutter to an open position which permits transmission of laser light to the optical fiber.

Abstract: A modulator apparatus for use in the preparation of bone surfaces and the implantation of a modular total knee prosthesis in a patient, which apparatus comprises cutting guides, templates, alignment devices, a distractor and clamping instruments which provide modularity and facilitate bone resection and prosthesis implantation.

Abstract: The invention provides antifungal agents of the formula: ##STR1## and their pharmaceutically acceptable salts, wherein R is phenyl optionally substituted by 1 to 3 substituents each independently selected from halo and CF.sub.3 ;R.sup.1 is C.sub.1 -C.sub.4 alkyl;R.sup.2 is H or C.sub.1 -C.sub.4 alkyl; and"Het", which is attached to the adjacent carbon atom by a ring carbon atom, is selected from pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl and triazinyl, "Het" being optionally substituted by C.sub.1 -C.sub.4 alkyl, C.sub.1 -C.sub.4 alkoxy, halo, CF.sub.3, CN, NO.sub.2, NH.sub.2, --NH(C.sub.1 -C.sub.4 alkanoyl) or --NHCO.sub.2 (C.sub.1 -C.sub.4 alkyl).

Abstract: Certain 1-heteroaryl-3-acyl-2-oxindoles wherein the acyl-substituent is thenoyl, furoyl, benzoyl or substituted benzoyl, are inhibitors of cycloxygenase and lipoxygenase enzymes and are useful as anti-inflammatory agents in mammals.

Abstract: There is disclosed a composition and method for removing dissolved oxygen from aqueous systems, for example, boiler water systems or oil injection water or brine. The disclosed method and composition uses a salt of a keto-gluconic acid, or a salt of a stereoisomer of a keto-gluconic acid, as the oxygen scavenger.

Abstract: A series of novel alkanesulphonamidophenyl-N-alkyl-N-(heterocyclic-alkyl)alkylamine derivatives have been prepared, including their pharmaceutically acceptable salts. These compounds are useful in therapy as anti-arrhythmic agents and therefore, are of value in the treatment of various cardiac arrhythmias. Said sulfonamide compounds are of the formula: ##STR1## wherein R and R.sup.1 are each C.sub.1 -C.sub.4 alkyl; X is --CH.sub.2 --, --CO-- or --CH(OH)--; n is two, three or four; and "Het" is a nitrogen-containing heterocyclic group wherein said heterocyclic group is preferably 2H-3,4-dihydroisoquinol-1-on-2-yl or 2H-isoquinol-1-on-2-yl, each optionally substituted with halogen or C.sub.1 -C.sub.4 alkyl.

Abstract: Antiparasitic compounds of formula (I): ##STR1## The broken line at the 22-23 position representing an optional double bond and either R.sup.1 is H or OH and the double bond is absent or the double bond is present and R.sup.1 is absent; R.sup.2 is optionally substituted phenyl, or a group of formula (II): ##STR2## wherein X is O, S or --CH.sub.2 --, abc and d are 0-2 and a+b+c+d.ltoreq.5 R.sup.3 is H or MeR.sup.4 is H, OH or 4'-(alpha-L-oleandrosyl)-alpha-L-oleandrosyloxy.The compounds are prepared by fermentation of Streptomyces avermitilis in the presence of an N-alkanoyl cysteamine thioester containing R.sup.2.

Abstract: A prosthetic part for use as an orthopedic implant has a base member defining an outer surface for implantation adjacent a prepared bone surface. The outer surface includes a recessed area having a predetermined shape and depth. A first rigid plate having this predetermined shape and having a plurality of elongated slots formed therein is fixedly attached within the recesssed area of the base member. A second rigid plate also having the same predetermined shape as the recess and also having a plurality of elongated slots formed therein is attached to the first rigid plate. The elongated slots of the second plate are angularly offset with respect to the elongated slots in the first plate to produce a controlled porosity. The thicknesses of the first and second plates are predetermined so that the outer surface of the second plate is continuous with the non-recessed outer surface of the base member.

Abstract: A modular prosthesis features at least one male-female fitting, with the female portion being located on one end of one segment of that prosthesis and the mating male portion being located on one end of a second prosthesis segment, with at least the proximal part of the male-female fitting having a taper. The two parts of that fitting can be locked together by a locking mechanism in the form of a novel spacer which also has a taper which mates with the taper of the male-female fitting described above. Multiple modular segments can be assembled together so as to produce a prosthesis as required by the patient.

Abstract: This invention relates to devices useful for the controlled delivery of one or more beneficial agents to an environment of use. More specifically, this invention concerns such devices which are powered by lyotropic liquid crystals. This invention also relates to the controlled delivery of one or more beneficial agents to an aqueous environment of use through the use of such lyotropic liquid crystal powered dispensing devices. Also disclosed are methods for the controlled delivery of one or more beneficial agents to an aqueous environment of use which comprise administering to or otherwise placing the devices of this invention in the environment of use.

Abstract: A prosthetic acetabular cup 100 includes a fixation element 102 for introduction into the acetabulum. The fixation element 102 has a concave inner surface with a generally circular base formed in a plane generally perpendicular to the central longitudinal axis. A bearing component 7 is formed from a deformable material and has a concave opening therein for receiving a spherical head of a prosthetic femoral component. The bearing component 7 has an outer surface that nests within the concave inner surface of the fixation element 102. A snap lock mechanism is used to lock the bearing component 7 within the fixation element 102 in the axial direction. Both the fixation element 102 and the bearing component 7 include a plurality of circumferentially spaced recesses 3, 12 located around a common pitch circle adjacent the generally circular base of the fixation element 102.

Abstract: A prosthetic part for use as an orthopaedic implant has a cast metal base member and a tissue ingrowth surface spaced outwardly therefrom. The tissue ingrowth surface is in the form of a cast metal lattice element which covers at least a part of the outer surface of the base member. The cast metal lattice element is cast simultaneously and integrally with the base member from the same metal. This metal may be any well known castable material for orthopaedic implants such as Vitallium or titanium. The lattice element is in the form of a grid-like mesh which includes spaced members cast integrally with the wire mesh and the base member to space the lattice element a predetermined distance above the prosthesis surface. An investment casting technique wherein a meltable material is coated with a ceramic casting shell is utilized to produce the integrally cast orthopaedic implant and tissue ingrowth surface.